1. Introduction {#sec1-biomolecules-09-00040}
===============

For females in both developed and developing countries, breast cancer (BC) has the second highest mortality rate after lung cancer. More than 1.3 million individuals are diagnosed with BC each year, and the mortality rate is 60% in developing countries \[[@B1-biomolecules-09-00040],[@B2-biomolecules-09-00040]\]. Some studies have reported that in American women, the probability of developing BC is 12.3% \[[@B3-biomolecules-09-00040]\]. Presently, various factors such as genetic predisposition, hormones, lifestyle, and age play an etiological role in this disease \[[@B4-biomolecules-09-00040]\]. Approximately 7% of patients with BC are diagnosed before age 40 years and the risk for BC increases with age. The most critical factors affecting the survival of patients with BC are the early diagnosis, tumour stage, and age \[[@B3-biomolecules-09-00040],[@B5-biomolecules-09-00040]\].

Mucins are high molecular weight glycoproteins, and are sub-classified into two structurally different groups: the secreted and the membrane-bound (transmembrane) mucins \[[@B6-biomolecules-09-00040]\]. Membrane-bound mucins act as a cell surface receptor for various signal transduction pathways. Secreted mucins form a protective layer and form a barrier against pathogens. Mucins are found in the mammary glands, liver, and in pancreas and kidney secretions, primarily in the respiratory and digestive system \[[@B7-biomolecules-09-00040]\]. Many studies have shown the altered expression of mucins in different pathological conditions, including cancer. The hypersecretion of mucins in cancers is due to their distinctive pattern of glycosylation, that serves as a binding platform for various growth factors and cytokines and thereby promotes the proliferation and metastasis of malignant cells through several signalling cascades. Each mucin has a specific role in tumour formation; some of the membrane-bound mucin (*MUC*) genes show hyperactivation and others show inactivation in pathological conditions. Membrane-bound mucin-2 (*MUC*2) is a secretory mucin, which is mainly in the gel format and is usually excreted in the digestive and respiratory tract \[[@B8-biomolecules-09-00040],[@B9-biomolecules-09-00040]\]. *MUC*2 overexpression is seen in mucinous carcinomas in organs such as the pancreas, breast, and prostate \[[@B10-biomolecules-09-00040],[@B11-biomolecules-09-00040],[@B12-biomolecules-09-00040]\]. Dhanisha et al. suggested that an increased level of mucin in the serum can be used as a potential marker for disease diagnosis and prognosis \[[@B6-biomolecules-09-00040]\].

In some preclinical studies, *MUC*2 expression was evaluated in breast cancer tissue \[[@B12-biomolecules-09-00040],[@B13-biomolecules-09-00040],[@B14-biomolecules-09-00040],[@B15-biomolecules-09-00040],[@B16-biomolecules-09-00040],[@B17-biomolecules-09-00040],[@B18-biomolecules-09-00040]\]. However, to the best of our knowledge, the clinical significance of serum *MUC*2 levels in breast cancer has not been previously examined. Therefore, this study was conducted to investigate the serum levels of *MUC*2 in BC patients and the relationship with tumour progression and known prognostic parameters.

2. Materials and Methods {#sec2-biomolecules-09-00040}
========================

2.1. Patients {#sec2dot1-biomolecules-09-00040}
-------------

In total, 127 female breast cancer patients admitted to Istanbul University, Institute of Oncology were enrolled in the study. Serum samples were obtained on the first admission before any type of treatment (chemotherapy, radiotherapy, hormonotherapy, or targeted therapy) was given to the patients. Written informed consent was obtained from all patients and healthy controls in order to obtain blood and to conduct *MUC*2 tests for their blood. The pretreatment evaluation included detailed clinical history and physical examination with a series of biochemistry tests, including serum lactate dehydrogenase (LDH) and Cancer Antigen 15-3 (CA15-3) levels. Diagnosis of breast cancer was histologically proven either with tru-cut biopsy of the primary lesion or metastatic site and staged according to the seventh edition of American Joint Committee on Cancer (AJCC). All the patients were treatment-naive for at least 3 months before accrual.

For histological evaluation, tissue sections (2 mm) were deparaffinized and stained using haematoxylin and eosin. Grading of tumours was established according to the modified Bloom-Richardson grading system. Estrogen receptor (ER), progesterone receptor (PR), and HER2 status was evaluated in the sample sections using appropriate antibodies. The immunohistochemical staining was assessed upon visual inspection with an optical microscope and considered as positive if the percentage of cells staining positive was more than 5%. Regarding HER2 evaluation, in the case of 2(+) staining by immunohistochemistry, HER2 gene amplification was analysed by fluorescent in situ hybridization (FISH).

All patients were treated with standard treatment modalities according to NCCN guidelines. Sixty-two patients received adjuvant treatment after mastectomy or lumpectomy. Another sixty-five patients with locally-advanced (*n* = 37) and metastatic disease (*n* = 28) were treated with anthracycline and/or taxane-based chemotherapy (CT) or single-agent capecitabine, and trastuzumab (if HER2 positive) with/without radiotherapy depending on the stage of the disease. Follow-up programs included clinical, laboratory, and radiological assessments performed at 8-week intervals during CT. Response to treatment was evaluated in patients who had metastatic disease or receiving neoadjuvant CT according to clinical examination and the revised RECIST criteria version 1.1. Those with complete or partial responses were considered as CT-responsive. Tumour (T) and Nodal (N) stages were recorded for only non-metastatic patients. While breast cancer has four transcriptional subtypes in the prediction analysis of microarray 50 (PAM50) scheme---luminal A, luminal B, basal-like, and human epidermal growth factor receptor 2 (HER2)-enriched (HER2E)---these subtypes overlap with immunohistochemical (IHC) staining of three protein markers, ER, PR, and HER2, supplemented with in situ hybridization (ISH) of HER2. The HER2E subtype captures some but not all HER2+ tumours \[[@B19-biomolecules-09-00040]\]. However, we categorized the patients according to molecular subtypes as; Her2-negative luminal (ER positive, HER2 negative), triple positive (ER, PR, and HER2 positive), triple negative (ER, PR, and HER2 negative), and HER2 disease (ER and PR negative, HER2 positive).

For comparison of serum levels of *MUC*2, age and sex-matched 40 healthy women controls were included in the analysis. Our study was found suitable and was approved on 9 March 2018 by the Ethics Committee of Istanbul Faculty of Medicine, Istanbul University with project number 2018/359.

2.2. Measurement of Serum MUC2 Levels {#sec2dot2-biomolecules-09-00040}
-------------------------------------

Blood samples were obtained from patients with breast cancer and healthy controls by venipuncture and clotted at room temperature. The sera were collected following centrifugation and frozen immediately at --80 °C until analysis. Serum *MUC*2 (USCN, Wuhan, China) levels were determined by the solid-phase sandwich ELISA method. The microtiter plate has been pre-coated with an antibody specific to *MUC*2. Standards and samples were added to the wells with a biotin-conjugated antibody specific to *MUC*2. Next, avidin conjugated to horseradish peroxidase (HRP) was added to each well and incubated. After tetramethylbenzidine (TMB) substrate solution was added, the wells that contain *MUC*2, biotin-conjugated antibody, and enzyme-conjugated avidin exhibited a change in colour. The enzyme substrate reaction was terminated by the addition of sulphuric acid solution and the colour change was measured spectrophotometrically (ChroMate® 4300; Awareness Technology, Inc., Palm City, FL, USA) at a wavelength of 450 nm. The concentration of *MUC*2 in the samples was then determined by comparing the optical density (OD) of the samples to the standard curve.

2.3. Statistical Analysis {#sec2dot3-biomolecules-09-00040}
-------------------------

Continuous variables were categorized using median values as the cut-off point. For assessment of relationships, comparisons between various clinical/laboratory parameters and serum levels of *MUC*2 assays were accomplished using Mann--Whitney U test since serum *MUC*2 had non-normal distribution in all groups. Survival was calculated from the date of the first admission to hospital to the death resulting from any cause or to the last contact with the patient or any family member. Kaplan--Meier method was used for estimation of survival of patient and differences in survivals were assessed by the log-rank statistic. A *p*-value less than 0.05 was accepted as statistically significant. Statistical analysis was carried out using IBM SPSS Statistics for Windows, Version 21.0 (Armonk, NY: IBM Corp. Released 2012, USA).

3. Results {#sec3-biomolecules-09-00040}
==========

Between July 2006 and June 2016, 127 female breast cancer patients were enrolled in the study. Median age of diagnosis was 50 (range: 26---8) ([Table 1](#biomolecules-09-00040-t001){ref-type="table"}). Twenty-eight (22%) patients were metastatic and the most frequent site of metastasis was bone (*n* = 17, 61%). The majority of the patients with non-metastatic disease had node-positive (*n* = 64, 65%) disease and most of them (*n* = 34, 34%) were of the N~1~ stage. The serum *MUC*2 levels showed a strong difference between the patients and the control group ([Table 2](#biomolecules-09-00040-t002){ref-type="table"}, [Figure 1](#biomolecules-09-00040-f001){ref-type="fig"}). Serum *MUC*2 levels were significantly higher than the controls (median level of 198 vs. 54 ng/mL, *p* \< 0.001). As a diagnostic test, the sensitivity and specificity of serum *MUC*2 levels was 74.8% and 75%, respectively, if the cut-off value was taken as 97.5 ng/mL (*p* \< 0.001) ([Figure 2](#biomolecules-09-00040-f002){ref-type="fig"}). Positive predictive value was 90.5% and negative predictive value was 48.4% according to the receiver operating characteristic (ROC) analysis.

[Table 3](#biomolecules-09-00040-t003){ref-type="table"} shows the correlation between the serum levels of *MUC*2 and clinicopathological factors. There were no significant correlations between serum *MUC*2 levels and any type of clinic-pathological and laboratory parameters (*p* \> 0.05).

Survival Analysis
-----------------

The median follow-up time was 65 months (range: 5--97 months). At the end of the observation period, 22 (17%) patients were dead. The mean survival for all patients was 85.0 ± 2.4 months (95% CI = 28.05--43.14) and 1-, 3-, and 5-year overall survival rates were 99% (95% CI = 87--97), 92% (95% CI = 97--101), and 85% (95% CI = 79--92), respectively. Negativity of ER and PR (*p* = 0.03 and *p* = 0.03, respectively), presence of triple-negative histology (*p* = 0.01), higher T stage (*p* = 0.03), elevated CA15-3 (*p* = 0.004), unresponsiveness to chemotherapy (*p* = 0.001), and presence of metastasis (*p* \< 0.001) were associated with worse survival ([Table 4](#biomolecules-09-00040-t004){ref-type="table"}). However, serum *MUC*2 levels were not associated with survival (*p* = 0.65) ([Figure 3](#biomolecules-09-00040-f003){ref-type="fig"}).

4. Discussion {#sec4-biomolecules-09-00040}
=============

In our study, we aimed to evaluate serum *MUC*2 levels in patients with breast cancer and age and sex-matched healthy controls. According to our results, serum *MUC*2 levels are higher in the BC patients than the control group. As far as we know, this is the first serum study of *MUC*2 in the literature so far.

*MUC*2 expression is absent in the ductal epithelium of the healthy breast \[[@B13-biomolecules-09-00040]\]. *MUC*2 is expressed in pre-malignant breast lesions like ductal carcinoma in situ (DCIS), and is upregulated in lobular carcinoma in situ (LCIS). Both membrane-bound (*MUC*1, *MUC*3, *MUC*4) and secreted mucins (*MUC*2, *MUC*5AC, *MUC*5B, *MUC*6) are upregulated in ductal adenocarcinoma of the breast. Some studies uncovered several unique roles of mucins, which include modulation in proliferative, invasive and metastatic potential of tumour cells, throughout the progression of breast cancer.

There are only a few studies that evaluated the clinical implication of *MUC*2 expression in breast cancer tissue. Walsh et al. reported that BC patients whose tumours were positive for *MUC*2 had a significantly shorter survival compared to those with *MUC*2 non-expressing tumours (49 vs. 75 months) \[[@B14-biomolecules-09-00040]\]. However, Rakha et al. found that there is no significant prognostic association in survival analysis with *MUC*2 expression in BC \[[@B15-biomolecules-09-00040]\]. Do et al. also reported that there is no significant prognostic association in survival analysis with *MUC*2 expression in BC regarding both overall survival (OS) and disease-free survival (DFS) \[[@B16-biomolecules-09-00040]\]. In our study, serum *MUC*2 levels were not associated with survival (*p* = 0.65) ([Figure 3](#biomolecules-09-00040-f003){ref-type="fig"}).

Rakha et al. reported a significant inverse association between *MUC*2 expression and ER status \[[@B15-biomolecules-09-00040]\]. Patel et al. found *MUC*2 negative tumours were associated with a higher histological grade \[[@B17-biomolecules-09-00040]\]. On the contrary, Ohashi et al. found no clinical implication regarding *MUC*2 expression in BC \[[@B18-biomolecules-09-00040]\]. We also did not notice any prognostic or clinical implication other than a possible diagnostic role of serum *MUC*2 levels.

The limitations of our study were that it was a single-centre, observational study, and other mucin levels were not evaluated. We did not consider the effects of radiotherapy, hormone therapy, or targeted therapies; these factors may have been affected our results.

5. Conclusions {#sec5-biomolecules-09-00040}
==============

We discovered that serum *MUC*2 levels play a diagnostic role, although we did not find any predictive and prognostic role in survival in BC patients. For use as a diagnostic or screening tool, serum levels of *MUC*2 should be studied on a larger scale.

Conceptualization, S.B. and S.K.; Data curation, S.B. and M.S.; Formal analysis, A.Z., M.Z.U., and S.K.; Methodology, S.B.; Supervision, S.K.; Validation, M.S., M.Z.U., and E.B.D.; Visualization, S.K.; Writing---original draft, E.B.D. and S.K.; Writing---review and editing, A.Z.

This research received no external funding.

The authors declare no conflict of interest.

![The values of serum *MUC*2 levels in patients with breast cancer and healthy controls (*p* \< 0.001).](biomolecules-09-00040-g001){#biomolecules-09-00040-f001}

![The receiver operating characteristic (ROC) analysis for serum *MUC*-2 levels (*p* \< 0.001). AUC (CI) = 0.82 (0.76--0.89), cut-off value = 97.5 ng/mL, PPV= 90.5%, NPV= 48.4%. AUC: area under the curve; CI: confidence interval; PPV: positive predictive value; NPV: negative predictive value.](biomolecules-09-00040-g002){#biomolecules-09-00040-f002}
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biomolecules-09-00040-t001_Table 1

###### 

Characteristics of the patients and disease.

  ---------------------------------------------------------------------
  Variables                                               *n*
  ------------------------------------------------------- -------------
  Number of patients                                      127

  Age, years\                                             62/65
  Median (range): 50 (26--78)\                            
  \<50/≥50                                                

  Grade\                                                  5/50/44
  1/2/3                                                   

  Estrogen Receptor\                                      31/96
  Negative/Positive                                       

  Progesteron Receptor\                                   48/79
  Negative/Positive                                       

  HER-2\                                                  97/30
  Negative/Positive                                       

  classification\                                         77/19/11/20
  Luminal/Triple-positive/Her-2 disease/Triple-negative   

  T stage \*\                                             34/58/4/3
  1/2/3/4                                                 

  N stage \*\                                             35/34/21/9
  0/1/2/3                                                 

  M stage\                                                99/28
  0/1                                                     

  Serum LDH level (ULN: 450 U/L)\                         83/44
  Normal/Elevated                                         

  Serum CA15-3 level (ULN: 35 U/mL)\                      97/30
  Normal/Elevated                                         

  Response to CT\                                         58/7
  Yes/No                                                  

  Last status\                                            105/22
  Alive/Dead                                              
  ---------------------------------------------------------------------

\* in 99 non-metastatic patients. LDH: lactate dehydrogenase, ULN: upper limit of normal, CT: chemotherapy.

biomolecules-09-00040-t002_Table 2

###### 

The values of membrane-bound mucin 2 (*MUC*2) in patients with breast cancer and healthy controls.

  -------------------------------------
  Data             Value
  ---------------- --------------------
  Assay            MUC2 level (ng/mL)

  Patients\        198 (4--468)
  Median (range)   

  Controls\        54 (1--210)
  Median (range)   

  *p*              \<0.001 \*\*
  -------------------------------------

\*\* *p* \< 0.05.

biomolecules-09-00040-t003_Table 3

###### 

Results (median and range) of comparisons between the factors and various clinical/laboratory parameters.

  ------------------------------------------------------------
  Variables                           *MUC*2 (ng/mL)    *p*
  ----------------------------------- ----------------- ------
  Age, years                                            

  Younger (\<50 years)                185.5 (8--640)    0.90

  Older (≥50 years)                   200.0 (4-668)     

  Grade                                                 

  I--II (Good--medium)                215 (10--668)     0.42

  III (Poor)                          183.5 (4--560)    

  Estrogen Receptor                                     

  Negative                            135 (4--560)      0.21

  Positive                            202.5 (8--668)    

  Progesteron Receptor                                  

  Negative                            184 (4--668)      0.43

  Positive                            205 (10--560)     

  HER-2                                                 

  Negative                            205 (8--668)      0.51

  Positive                            160 (4--560)      

  Classification\                     \                 \
  HER-2 -negative luminal\            205 (8--668)\     0.46
  Others                              160 (4--560)      

  Classification\                     \                 \
  Triple-positive\                    183 (50--560)\    0.73
  Others                              201.5 (4--668)    

  Classification                                        

  HER-2 disease\                      96 (4--475)\      0.13
  Others                              202.5 (8--668)    

  Classification\                     \                 0.77
  Triple-negative\                    196 (38--560)\    
  Others                              198 (4--668)      

  T stage                                               

  1 (small)                           234 (10--496)     0.41

  2-4 (large)                         185 (4--668)      

  N status                                              

  Negative                            234 (10--490)     0.66

  Positive                            190.5 (4--668)    

  M stage                                               

  M0                                  198 (4--668)      0.65

  M1                                  195 (20--640)     

  Serum LDH level (ULN: 450 U/L)                        

  Normal                              200 (10--668)     0.47

  Elevated                            175 (4--640)      

  Serum CA15-3 level (ULN: 35 U/mL)                     

  Normal                              198 (4--668)      0.84

  Elevated                            200.5 (14--560)   

  Response to CT                                        

  Yes\                                184.5 (8--668)\   0.53
  No                                  270 (50--400)     
  ------------------------------------------------------------

LDH: lactate dehydrogenase, ULN: upper limit of normal; CT: chemotherapy.

biomolecules-09-00040-t004_Table 4

###### 

Univariate analyses of survival.

  ------------------------------------------------------------------------------------------------
  Variables                           Mean Survival\   3-Year Survival Rate (SE)\   *p*
                                      (SE)\            %                            
                                      Months                                        
  ----------------------------------- ---------------- ---------------------------- --------------
  Age of patients                                                                   

  \<50 years                          84.9 (3.1)       94.7 (3.0)                   0.69

  ≥50 years                           84.8 (3.4)       89.6 (4.0)                   

  Grade                                                                             

  I--II                               89.8 (2.4)       97.4 (2.5)                   0.26

  III                                 82.0 (3.1)       91.8 (3.9)                   

  Estrogen Receptor                                                                 

  Negative                            77.7 (5.7)       82.8 (7.0)                   0.03 \*\*

  Positive                            87.2 (2.5)       95.3 (2.3)                   

  Progesteron Receptor                                                              

  Negative                            80.5 (4.5)       84.8 (5.3)                   0.03 \*\*

  Positive                            87.0 (2.4)       97.1 (2.0)                   

  HER-2                                                                             

  Negative                            84.0 (2.8)       89.8 (3.2)                   0.56

  Positive                            87.7 (3.8)       92.6 (5.0)                   

  Classification                                                                    

  Luminal                             86.9 (2.8)       94.3 (2.8)                   0.19

  Others                              81.8 (4.1)       88.9 (4.7)                   

  Classification                                                                    

  Triple-positive                     83.1 (4.4)       100                          0.49

  Others                              84.4 (2.6)       90.9 (2.9)                   

  Classification                                                                    

  HER2 disease                        86.2 (6.3)       NR                           0.86

  Others                              84.7 (2.6)       91.4 (2.8)                   

  Classification\                     \                \                            \
  Triple-negative\                    69.1 (7.5)\      72.2 (10.6)\                 0.01 \*\*
  Others                              87.3 (2.3)       95.9 (2.0)                   

  T stage                                                                           

  T1                                  90.0 (0.8)       NR                           0.03 \*\*

  T2--T4                              84.7 (3.0)       91.7 (3.6)                   

  Node status                                                                       

  Negative                            96.8 (3.2)       87.3 (2.5)                   0.24

  Positive                            93.2 (3.3)       85.1 (2.9)                   

  M stage                                                                           

  M0                                  86.9 (2.1)       94.5 (2.4)                   \<0.001 \*\*

  M1                                  70.6 (6.6)       82.6 (7.9)                   

  Serum LDH level (ULN: 450 U/L)                                                    

  Normal                              87.6 (2.7)       92.2 (3.1)                   0.07

  Elevated                            77.1 (3.8)       92.3 (4.3)                   

  Serum CA15-3 level (ULN: 35 U/mL)                                                 

  Normal                              87.5 (2.3)       95.4 (2.3)                   0.004 \*\*

  Elevated                            75.9 (6.0)       82.6 (7.1)                   

  Response to CT                                                                    

  Yes                                 82.1 (3.8)       91.8 (3.9)                   0.001 \*\*

  No                                  47.0 (12.4)      57.1 (18.7)                  

  Serum MUC2 level                                                                  

  Elevated (\>median)                 83.7 (4.1)       89.5 (5,0)                   0.65

  Normal (\<median)                   85.2 (2.8)       93.5 (2.8)                   
  ------------------------------------------------------------------------------------------------

\*\* *p* \< 0.05. Abbreviations, LDH: lactate dehydrogenase; ULN: upper limit of normal; CT: chemotherapy.
